Log in
Enquire now

List of Merck patents

List of Merck patents
List of Celcuity patents
List of Oncimmune patents
List of BioNTech patents
List of companies in Half Court Ventures's investment portfolio
List of companies in David Marcus (entrepreneur)'s investment portfolio
Patents where
Current Assignee
Name
is
MerckMerck
Name
Description
Patent Applicant
Current Assignee
Inventor
Patent Jurisdiction
Patent Number
Date of Patent
‌
US Patent 10927086 Substituted sulfoximine compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors

Patent 10927086 was granted and assigned to Merck on February, 2021 by the United States Patent and Trademark Office.

Merck
Merck
United States Patent and Trademark Office
United States Patent and Trademark Office
10927086
February 23, 2021
‌
US Patent 10435398 Oxazole orexin receptor antagonists

Patent 10435398 was granted and assigned to Merck on October, 2019 by the United States Patent and Trademark Office.

Merck
Merck
United States Patent and Trademark Office
United States Patent and Trademark Office
10435398
October 8, 2019
‌
US Patent 10471126 Pegylated interleukin-10

Patent 10471126 was granted and assigned to Merck on November, 2019 by the United States Patent and Trademark Office.

Merck
Merck
United States Patent and Trademark Office
United States Patent and Trademark Office
10471126
November 12, 2019
‌
US Patent 9566345 Mono- and di-peg IL-10 production; and uses

Patent 9566345 was granted and assigned to Merck on February, 2017 by the United States Patent and Trademark Office.

Merck
Merck
United States Patent and Trademark Office
United States Patent and Trademark Office
9566345
February 14, 2017
‌
US Patent 9573913 Cathepsin cysteine protease inhibitors

Patent 9573913 was granted and assigned to Merck on February, 2017 by the United States Patent and Trademark Office.

Merck
Merck
United States Patent and Trademark Office
United States Patent and Trademark Office
9573913
February 21, 2017
‌
US Patent 9527838 2-pyridinecarboxamide derivatives, compositions containing such compounds, and methods of treatment

Patent 9527838 was granted and assigned to Merck on December, 2016 by the United States Patent and Trademark Office.

Merck
Merck
United States Patent and Trademark Office
United States Patent and Trademark Office
9527838
December 27, 2016
‌
US Patent 8518907 RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)

Patent 8518907 was granted and assigned to Merck on August, 2013 by the United States Patent and Trademark Office.

Merck
Merck
United States Patent and Trademark Office
United States Patent and Trademark Office
8518907
August 27, 2013
7 results
0 selected
7 results
0 selected
Golden logo

Company

  • Home
  • Pricing
  • Become an Editor
  • Enterprise

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us

Explore companies

  • Artificial Intelligence
  • Fintech
  • Biotechnology
  • Cybersecurity
  • Semiconductors
  • Electric Vehicles
  • Cloud Computing
  • Robotics
  • SaaS
  • Renewable Energy
  • Venture Capital
  • Blockchain
  • Browse all →